These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 27373855)
1. Patient stratification and the unmet need in asthma. Swedin L; Saarne T; Rehnberg M; Glader P; Niedzielska M; Johansson G; Hazon P; Catley MC Pharmacol Ther; 2017 Jan; 169():13-34. PubMed ID: 27373855 [TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies for the treatment of asthma. Catley MC; Coote J; Bari M; Tomlinson KL Pharmacol Ther; 2011 Dec; 132(3):333-51. PubMed ID: 21944943 [TBL] [Abstract][Full Text] [Related]
3. Biologic and New Therapies in Asthma. Tabatabaian F; Ledford DK; Casale TB Immunol Allergy Clin North Am; 2017 May; 37(2):329-343. PubMed ID: 28366480 [TBL] [Abstract][Full Text] [Related]
4. Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies. Chung KF J Intern Med; 2016 Feb; 279(2):192-204. PubMed ID: 26076339 [TBL] [Abstract][Full Text] [Related]
5. What goes up must come down: biomarkers and novel biologicals in severe asthma. Hilvering B; Pavord ID Clin Exp Allergy; 2015 Jul; 45(7):1162-9. PubMed ID: 25640208 [TBL] [Abstract][Full Text] [Related]
6. Characterization of asthma endotypes: implications for therapy. Stokes JR; Casale TB Ann Allergy Asthma Immunol; 2016 Aug; 117(2):121-5. PubMed ID: 27499539 [TBL] [Abstract][Full Text] [Related]
7. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. Fajt ML; Wenzel SE J Allergy Clin Immunol; 2015 Feb; 135(2):299-310; quiz 311. PubMed ID: 25662302 [TBL] [Abstract][Full Text] [Related]
8. Phenotypes and endotypes of uncontrolled severe asthma: new treatments. Campo P; Rodríguez F; Sánchez-García S; Barranco P; Quirce S; Pérez-Francés C; Gómez-Torrijos E; Cárdenas R; Olaguibel JM; Delgado J; ; J Investig Allergol Clin Immunol; 2013; 23(2):76-88; quiz 1 p. follow 88. PubMed ID: 23654073 [TBL] [Abstract][Full Text] [Related]
9. A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma. Bagnasco D; Ferrando M; Varricchi G; Passalacqua G; Canonica GW Int Arch Allergy Immunol; 2016; 170(2):122-31. PubMed ID: 27637004 [TBL] [Abstract][Full Text] [Related]
10. Targeted Therapy for Severe Asthma: Identifying the Right Patients. Low K; Bardin PG Mol Diagn Ther; 2017 Jun; 21(3):235-247. PubMed ID: 28044257 [TBL] [Abstract][Full Text] [Related]
11. T2-low asthma: current approach to diagnosis and therapy. Samitas K; Zervas E; Gaga M Curr Opin Pulm Med; 2017 Jan; 23(1):48-55. PubMed ID: 27798418 [TBL] [Abstract][Full Text] [Related]
15. Different endotypes and phenotypes drive the heterogeneity in severe asthma. McDowell PJ; Heaney LG Allergy; 2020 Feb; 75(2):302-310. PubMed ID: 31267562 [TBL] [Abstract][Full Text] [Related]
16. Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma? De Ferrari L; Chiappori A; Bagnasco D; Riccio AM; Passalacqua G; Canonica GW Expert Rev Respir Med; 2016; 10(1):29-38. PubMed ID: 26566089 [TBL] [Abstract][Full Text] [Related]
17. Biologic Therapy and Novel Molecular Targets of Severe Asthma. Pepper AN; Renz H; Casale TB; Garn H J Allergy Clin Immunol Pract; 2017; 5(4):909-916. PubMed ID: 28689841 [TBL] [Abstract][Full Text] [Related]
18. Cytokine-directed therapy in asthma. Ichinose M; Barnes PJ Curr Drug Targets Inflamm Allergy; 2004 Sep; 3(3):263-9. PubMed ID: 15379594 [TBL] [Abstract][Full Text] [Related]
19. Increased serum IL-17A and Th2 cytokine levels in patients with severe uncontrolled asthma. Hasegawa T; Uga H; Mori A; Kurata H Eur Cytokine Netw; 2017 Mar; 28(1):8-18. PubMed ID: 28840844 [TBL] [Abstract][Full Text] [Related]
20. Severe asthma: advances in current management and future therapy. Barnes PJ J Allergy Clin Immunol; 2012 Jan; 129(1):48-59. PubMed ID: 22196524 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]